Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2016-07-07 Regulatory Filings
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo welcomes increased access to treatment for patients with opioid dependence in the US
Regulatory Filings Classification · 1% confidence The document is titled "Press release" and discusses a company's reaction to a US government announcement regarding opioid treatment access. It contains forward-looking statements, company background, and contact information. Crucially, the final paragraph states: "This is information is information that Orexo AB is obliged to make public pursuant to the EU Market Abuse Regulation." This strongly suggests it is a mandatory regulatory disclosure intended for immediate public dissemination, rather than a detailed financial report (like 10-K or IR) or a specific shareholder communication (like DEF 14A or AGM-R). Since it is a general announcement mandated by regulation that doesn't fit the more specific categories (like ER, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length is short (3384 chars), which also supports it being an announcement rather than a full report.
2016-07-07 English
Orexo tecknar licensavtal som ger Mundipharma globala rättigheter till Zubsolv® utanför USA
Capital/Financing Update Classification · 1% confidence The document is a press release ("Pressmeddelande") dated June 30, 2016, announcing that Orexo AB has signed a licensing agreement with Mundipharma for global rights (ex-US) to Zubsolv®. This involves financial terms (upfront payment, milestones, royalties) and strategic partnership details. This type of announcement, detailing a significant business transaction, financing arrangement, or strategic partnership, aligns best with the 'Capital/Financing Update' (CAP) category, as it directly impacts the company's future revenue streams and capital structure through licensing fees and royalties. While it is a press release, it is highly specific to a major commercial/financing deal, making CAP more precise than the general 'RNS' fallback. It is not an earnings release (ER), an interim report (IR), or a formal regulatory filing like a 10-K.
2016-06-30 Swedish
Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv®
M&A Activity Classification · 1% confidence The document is a press release dated June 30, 2016, announcing a significant business event: Orexo signing a license agreement with Mundipharma for ex-US global rights to Zubsolv®. This involves upfront payments, milestone payments, and royalties, which directly relates to the company's financing, capital structure, and strategic partnerships. This fits best under the 'Capital/Financing Update' category, as it details a major commercial and financial transaction. It is not an Earnings Release (ER) as it focuses on a deal, not period results. It is not a 10-K or IR as it is a short press release about a specific event. It is not a general Regulatory Filing (RNS) because 'CAP' is a more specific fit for a major licensing/financing deal.
2016-06-30 English
Orexo sees very limited exposure to the UK and the British pound
Capital/Financing Update Classification · 1% confidence The document is a short press release dated June 21, 2016, issued by Orexo AB (publ) to clarify its limited financial exposure to the UK and the British Pound (GBP) in response to media attention regarding Brexit. It discusses royalty income structure and historical milestone payments. This type of immediate, specific operational/financial clarification, often issued outside of standard quarterly/annual reporting cycles, fits best under a general regulatory announcement category. Since it is not a full Earnings Release (ER), Interim Report (IR), or a specific transaction notice (like DIV, CAP, DIRS), the most appropriate classification is the general regulatory filing category, RNS, as it serves as a timely disclosure of material information to the market. It is too specific for a general 'Management Report' (MDA) and too brief/informal for a formal 'Earnings Release' (ER). Given the context of immediate market clarification, RNS is the best fit.
2016-06-21 English
Orexos exponering mot UK och det brittiska pundet är ytterst begränsad
Regulatory Filings Classification · 1% confidence The document is a short press release dated June 21, 2016, issued by Orexo AB. The content specifically addresses market concerns regarding the company's exposure to Brexit and the British Pound (GBP), clarifying that the exposure is limited. This type of communication, which provides specific, timely operational or financial clarification outside of a standard periodic report (like 10-K or IR), often falls under general regulatory announcements or investor relations updates. Since it is not a formal earnings release (ER), a capital change (CAP/SHA), or a director dealing report (DIRS), and it is a direct statement to the market regarding a specific financial/operational risk factor, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially an Investor Presentation (IP) if it were more strategic, but its brevity and reactive nature point towards RNS. Given the options, RNS is the most appropriate fallback for a specific, non-standard regulatory clarification.
2016-06-21 Swedish
Orexo to present at Jefferies 2016 Healthcare Conference, NYC
Regulatory Filings Classification · 1% confidence The document is a short announcement from Orexo AB stating that its CFO and President of the US subsidiary will present at the '2016 Jefferies Healthcare Conference' on June 8, 2016. This is an announcement about participation in an external industry event, not a formal regulatory filing, earnings release, or a report itself. It does not fit the definitions for 10-K, ER, IR, or CT. Since it is an announcement regarding company activity and investor relations, and it doesn't fit a more specific category like DIV or DIRS, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if the content was the presentation itself. However, since it is merely announcing attendance and a presentation time, and the presentation itself will be made available later, it functions as a general corporate update. Given the options, RNS (Regulatory Filings / miscellaneous announcements) is the most appropriate fallback for this type of event announcement that isn't a core financial report or a specific insider/dividend action. The document length is very short (1787 chars), supporting the idea that it is an announcement rather than a full report.
2016-05-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.